Novo Nordisk stated that post hoc analyses of its CagriSema REDEFINE 1 trial are hypothesis-generating and require further study to confirm the results

Overview Debates Related claims Topics Sources

Study authors proposed bariatric surgery serve as a first-line treatment for clinical obesity, but as a second-line risk-reduction option for preclinical obesity as pharmacotherapy expands.

Clinical obesity prevalence among metabolic bariatric surgery candidates varied across international centers, ranging from 62.7% in the Brazilian cohort to 79.3% in the United Kingdom cohort.

Mean body mass index and distribution across BMI categories (<40, 40-49, and ≥50) did not differ significantly between clinical and preclinical obesity groups within surgical centers.

Study authors noted bariatric surgery in clinical obesity may offer faster economic returns due to reduced post-operative complications, decreased medication use, and fewer hospitalizations.

Bariatric surgery patients with clinical obesity lost modestly less weight post-surgery, trailing preclinical obesity patients by 2 to 4 percentage points in several study cohorts at 12 and 24 months.

Study authors stated bariatric surgery for preclinical obesity should be evaluated as a preventive intervention with longer time horizons and distinct cost-effectiveness thresholds.

Study authors suggested health systems with limited surgical capacity prioritize metabolic bariatric surgery for patients demonstrating clinical obesity-related organ dysfunction.

A Lancet Diabetes & Endocrinology Commission led by Dr. Francesco Rubino in January 2025 proposed separating clinical obesity from preclinical obesity based on organ dysfunction.

Investigators evaluated 2,316 adult gastric bypass and sleeve gastrectomy patients from centers in London, Barcelona, Lille, and São Paulo using the Lancet Diabetes & Endocrinology framework.

Patients with clinical obesity experienced higher baseline American Society of Anesthesiologists surgical risk classifications across all four international study cohorts compared to preclinical obesity patients.

In the French cohort analyzed in the study, major 30-day post-operative complications occurred in 4.0% of clinical obesity patients compared to 1.1% of preclinical obesity patients.

A JAMA Network Open study of 2,316 adults undergoing metabolic bariatric surgery between 2014 and 2025 found that 73.8% (1,709 patients) met criteria for clinical obesity.

A post hoc analysis of 1,902 women by menopausal status showed CagriSema produced 26.7% weight loss in premenopausal, 24.8% in perimenopausal, and 23.1% in postmenopausal women at 68 weeks, versus approximately 2% for placebo

CagriSema is an experimental weekly injection combining GLP-1 receptor agonist semaglutide with cagrilintide, a drug targeting the amylin pathway to mimic pancreatic hormones that regulate hunger and fullness

Investors previously responded coolly to CagriSema after initial overall phase 3 trial results showed a 22.7% weight loss, falling below Novo Nordisk's targeted 25% expectation

The phase 3 REDEFINE 1 trial of CagriSema in over 3,400 adults resulted in an average weight loss of 22.7% at 68 weeks compared to 2.3% for placebo, with women comprising approximately 67% of participants

Novo Nordisk announced on October 20, 2026, that REDEFINE 1 trial post-study analyses of 2,309 women with obesity or overweight receiving 2.4 mg CagriSema showed 25% average weight loss at 68 weeks versus 3% for placebo under uninterrupted treatment

Novo Nordisk interim head of clinical development Michelle Skinner Moore stated that exploring investigational products like CagriSema across the reproductive lifespan is important due to menopausal weight gain

Novo Nordisk presented the REDEFINE 1 trial's female participant data for CagriSema at the annual meeting of The Menopause Society in San Diego

Wall Street analysts compiled by FactSet project CagriSema to generate $11.84 billion in global sales for obesity treatment in 2028